FDA approves perioperative pembrolizumab for head and neck cancer — the first approval for this cancer in 6 years

Research type: High-Certainty EvidenceRegulatory status: FDA-approved for the exact stated cancer/useGuideline status: Not addressed

In plain English

The 30-second version

What happened?

In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and neck squamous cell carcinoma -- median 51.8 months versus 30.4 months with standard of care alone -- a real, statistically significant improvement on the trial's primary endpoint, and the first FDA approval for this cancer type in six years.

Why does it matter?

A confirmed, randomized phase 3 trial with a statistically significant primary-endpoint result -- converting the standard of care for a genuinely underserved cancer type that had gone six years without a new FDA approval and zero prior coverage on this site.

What does this not prove?

This approval is specifically for patients whose tumors are PD-L1-positive (CPS >=1) and whose disease is resectable (surgically removable) -- it does not apply to PD-L1-negative disease or to unresectable/metastatic head and neck cancer, which are addressed by other, separate treatment approaches.

Keep reading for evidence stage, limitations, study details, and sources.

The FDA approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1, to be given before surgery (neoadjuvant), then continued after surgery alongside radiotherapy (with or without chemotherapy), then as a single agent (adjuvant) — the first FDA approval for HNSCC in six years, and the first-ever perioperative (both before and after surgery) approval for locally advanced HNSCC. The approval was based on the randomized, open-label, phase 3 KEYNOTE-689 trial (ClinicalTrials.gov NCT03765918; primary publication in the New England Journal of Medicine, DOI 10.1056/NEJMoa2415434, PMID 40532178), which randomized 714 patients with stage III-IVA resectable HNSCC across 192 sites. Event-free survival — the trial’s primary endpoint — was significantly longer with pembrolizumab: median 51.8 months versus 30.4 months with standard of care alone, a statistically significant improvement. Adding pembrolizumab before surgery did not reduce the likelihood that surgery could be completed, and no new safety signals were identified.

Population / Applicability

Studied in: Adults with stage III-IVA resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1, randomized to perioperative pembrolizumab (before and after surgery) plus standard of care, or standard of care alone, at 192 sites in North America, South America, and Europe, in the phase 3 KEYNOTE-689 trial. (Adults)

Requires PD-L1 testing (CPS >=1) before use. Adding pembrolizumab before surgery did not reduce the likelihood that surgery could be completed and no new safety signals were identified in the trial, but this record has not independently reviewed the full safety/tolerability profile.

Full evidence details
Study design
Randomized controlled trial
Sample size
714

Funding & Conflicts

Sponsor/developer: Merck & Co., Inc. -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Adults with resectable, locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS >=1), as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (with or without cisplatin), then as a single agent.
Biomarker requirement
PD-L1 CPS >=1
Decision date
2025-06-12
Source
Company press release (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Last reviewed

Related discoveries

FDA approves perioperative pembrolizumab for head and neck cancer — the first approval for this cancer in 6 years

https://cancerdiscoveries.com/discoveries/fda-approves-perioperative-pembrolizumab-for-head-and-neck-cancer-the-first-approval-for-this-cancer-in-6-years/

Research type: High-Certainty Evidence

What This Means

In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and neck squamous cell carcinoma -- median 51.8 months versus 30.4 months with standard of care alone -- a real, statistically significant improvement on the trial's primary endpoint, and the first FDA approval for this cancer type in six years.

What This Doesn't Mean

This approval is specifically for patients whose tumors are PD-L1-positive (CPS >=1) and whose disease is resectable (surgically removable) -- it does not apply to PD-L1-negative disease or to unresectable/metastatic head and neck cancer, which are addressed by other, separate treatment approaches.

Why It Matters

A confirmed, randomized phase 3 trial with a statistically significant primary-endpoint result -- converting the standard of care for a genuinely underserved cancer type that had gone six years without a new FDA approval and zero prior coverage on this site.

Primary sources

  • Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (New England Journal of Medicine) — https://doi.org/10.1056/NEJMoa2415434 (DOI 10.1056/NEJMoa2415434, PMID 40532178)

Date verified: 2026-08-13

Correction status: No correction or retraction